Comparative efficacy of mono- and combined therapy for idiopathic short stature with delayed puberty
Background. Growth hormone therapy for idiopathic short stature (ISS) is a subject of debate, because of the heterogeneous endocrine profile in these children. The purpose of this work was to evaluate the effectiveness of mono- (testosterone enanthate) and combined therapy (testosterone enanthate and recombinant growth hormone) in adolescents with idiopathic short stature. Materials and methods. The examined youths of Uzbek population (n = 46) with constitutional delay in growth and puberty aged 14.8–16.2 years were divided into three groups in accordance with the type of treatment. Results. It was found that recombinant growth hormone (somatropin) therapy (0.033 mg/kg/day) in combination with testosterone enanthate (50 mg once every 21 days) is effective and increases the rate of growth in idiopathic short stature with delayed puberty. Conclusions. Monotherapy with testosterone enanthate at a low dose significantly increases the rate of growth in boys with constitutional delay in growth and puberty, compared with the group without treatment, but is significantly less effective than in the group of combined therapy.
Full Text:PDF (Русский)
Cohen P, Rogol AD, Deal CL, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. 2008 Nov;93(11):4210-7. doi: 10.1210/jc.2008-0509.
Bolshova O, Samson O, Sprynchuk N, Muz V, Tkachova T, Antropova O. Idiopathic short stature: Clinical-diagnostic criteria. Klinicna endokrinologia ta endokrinna hirurgia. 2013;(42):52-58. (in Ukrainian).
Wit JM, Clayton PE, Rogol AD, Savage MO, Saenger PH, Cohen P. Idiopathic short stature: definition, epidemiology, and diagnostic evaluation. Growth Horm IGF Res. 2008 Apr;18(2):89-110. doi: 10.1016/j.ghir.2007.11.004.
Binder G, Schwarze CP, Ranke MB. Identification of short stature caused by SHOX defects and therapeutic effect of recombinant human growth hormone. J Clin Endocrinol Metab. 2000 Jan;85(1):245-9. doi: 10.1210/jcem.85.1.6375.
Hujeirat Y, Hess O, Shalev S, Tenenbaum-Rakover Y. Growth hormone receptor sequence changes do not play a role in determining height in children with idiopathic short stature. Horm Res. 2006;65(4):210-216. doi: 10.1159/000092514.
Goddard AD, Covello R, Luoh SM, et al. Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group. N Engl J Med. 1995 Oct 26;333(17):1093-8. doi: 10.1056/NEJM199510263331701.
Attie KM, Carlsson LM, Rundle AC, Sherman BM. Evidence for partial growth hormone insensitivity among patients with idiopathic short stature. The National Cooperative Growth Study. J Pediatr. 1995 Aug;127(2):244-50.
Cianfarani S, Liguori A, Boemi S, et al. Inaccuracy of insulin-like growth factor (IGF) binding protein (IGFBP)-3 assessment in the diagnosis of growth hormone (GH) deficiency from childhood to young adulthood: association to low GH dependency of IGF-II and presence of circulating IGFBP-3 18-kilodalton fragment. J Clin Endocrinol Metab. 2005 Nov;90(11):6028-34. doi: 10.1210/jc.2005-0721.
Chaplin JE, Kristrom B, Jonsson B, et al. Improvements in behaviour and self-esteem following growth hormone treatment in short prepubertal children. Horm Res Paediatr. 2011;75(4):291-303. doi: 10.1159/000322937.
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2020